Faculty

Tassos Dimou, M.D.

Clinical Studies

A Phase 2 Study To Investigate Ubamatamab With And Without Marlotamig (REGN7075) In Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Jacksonville, FL Rochester, MN This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab.

The study is looking at:

* How well ubamatamab and marlotamig work(s)
* The side effects that ubamatamab and marlotamig might cause
* How much ubamatamab and marlotamig is in the blood at different times
* If the body makes antibodies to ubamatamab and/or marlotamig, this may cause the ubamatamab to not work as well
A Phase 2b, Open-Label, Two-cohort Study Of Subcutaneous Amivantamab In Combination With Lazertinib As First-Line Treatment, Or Subcutaneous Amivantamab In Combination With Platinum-Based Chemotherapy As Second-line Treatment, For Common EGFR-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Jacksonville, FL Rochester, MN
The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

A Phase 1/2 Study To Assess BDTX-1535, An Oral EGFR Inhibitor, In Patients With Glioblastoma Or Non-Small Cell Lung Cancer Jacksonville, FL Rochester, MN BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.

Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
A Single-Arm, Open-Label, Multicenter Phase 2 Study To Evaluate The Efficacy And Safety Of Taletrectinib In Patients With Advanced Or Metastatic ROS1 Positive NSCLC And Other Solid Tumors Rochester, MN
The main purpose of the study is to evaluate safety and effectiveness of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.